Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Windlas Biotech Ltd.
Swot
Windlas Biotech Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Windlas Biotech Ltd. has 25 Strengths, 4 Weaknesses, 1 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(25)
Weakness
(4)
Opportunity
(1)
Threats
(1)
Others
(3)
Price crossing above SMA20 today, and greater than SMA5
Strong Momentum: Price above short, medium and long term moving averages
Consistent Highest Return Stocks over Five Years - Nifty500
Mid-range Performer (DVM)
Relative Outperformance versus Industry over 1 Month
Stocks whose current price is 20% higher than week low, and more than previous close
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Stocks gaining versus previous close, open price and RSI
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Increasing Revenue every Quarter for the past 8 Quarters
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Companies with Low Debt
Increasing Revenue every Quarter for the past 4 Quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Highest Recovery from 52 Week Low
RSI indicating price strength
Biggest Price Gainers from Open
Stocks Outperforming their Industry Price Change in the Quarter
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Declining Net Cash Flow : Companies not able to generate net cash
Top Losers
Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV
FII / FPI or Institutions increasing their shareholding
MFs decreased their shareholding last quarter
Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
Decline in Net Profit with falling Profit Margin (QoQ)
